Novo Nordisk Raises 2012 Forecast as Profit Beats Estimates

Novo Nordisk A/S, the world’s largest insulin maker, raised its full-year sales and profit forecasts after reporting second-quarter earnings that beat analysts’ estimates. The shares rose to a record.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.